BR112014014464A2 - uso de n-hidroxisuccinimida para melhorar a estabilidade do conjugado - Google Patents
uso de n-hidroxisuccinimida para melhorar a estabilidade do conjugadoInfo
- Publication number
- BR112014014464A2 BR112014014464A2 BR112014014464A BR112014014464A BR112014014464A2 BR 112014014464 A2 BR112014014464 A2 BR 112014014464A2 BR 112014014464 A BR112014014464 A BR 112014014464A BR 112014014464 A BR112014014464 A BR 112014014464A BR 112014014464 A2 BR112014014464 A2 BR 112014014464A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxysuccinimide
- nhs
- conjugate stability
- stability
- improve conjugate
- Prior art date
Links
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000007098 aminolysis reaction Methods 0.000 abstract 1
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000006011 modification reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570139P | 2011-12-13 | 2011-12-13 | |
| PCT/US2012/069527 WO2013090590A1 (en) | 2011-12-13 | 2012-12-13 | Use of n-hydroxysuccinimide to improve conjugate stability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014014464A8 BR112014014464A8 (pt) | 2017-06-13 |
| BR112014014464A2 true BR112014014464A2 (pt) | 2017-06-13 |
Family
ID=48613179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014464A BR112014014464A2 (pt) | 2011-12-13 | 2012-12-13 | uso de n-hidroxisuccinimida para melhorar a estabilidade do conjugado |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140350228A1 (enExample) |
| EP (1) | EP2790724A4 (enExample) |
| JP (1) | JP2015504869A (enExample) |
| KR (1) | KR20140107418A (enExample) |
| CN (1) | CN104093425A (enExample) |
| AU (1) | AU2012352210A1 (enExample) |
| BR (1) | BR112014014464A2 (enExample) |
| CA (1) | CA2859444A1 (enExample) |
| EA (1) | EA201491173A1 (enExample) |
| HK (1) | HK1203364A1 (enExample) |
| IL (1) | IL233086A0 (enExample) |
| MX (1) | MX2014007125A (enExample) |
| SG (2) | SG10201604747WA (enExample) |
| WO (1) | WO2013090590A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ595430A (en) | 2005-08-24 | 2013-05-31 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
| KR101947176B1 (ko) | 2009-06-03 | 2019-02-12 | 이뮤노젠 아이엔씨 | 접합 방법 |
| EA201991268A3 (ru) | 2011-03-29 | 2020-01-31 | Иммуноджен, Инк. | Получение конъюгатов "майтансиноид-антитело" одностадийным способом |
| HK1213288A1 (zh) | 2012-10-04 | 2016-06-30 | Immunogen, Inc. | 使用pvdf膜純化細胞結合劑細胞毒性劑綴合物 |
| JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| CN106267225B (zh) * | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
| EP3442595A1 (en) | 2016-04-14 | 2019-02-20 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
| GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| CN113336823A (zh) * | 2021-05-28 | 2021-09-03 | 联宁（苏州）生物制药有限公司 | 一种用于抗体偶联药物连接子lnd1067的合成方法 |
| WO2025151380A1 (en) * | 2024-01-08 | 2025-07-17 | Azvlz, Inc. | Functionalized conjugation crosslinkers and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2835829B1 (fr) * | 2002-02-13 | 2007-09-14 | Centre Nat Rech Scient | Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications |
| DE10242076A1 (de) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | HAS-Allergen-Konjugate |
| NZ595430A (en) * | 2005-08-24 | 2013-05-31 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
| US7928113B2 (en) * | 2005-11-14 | 2011-04-19 | University Of Southern California | Integrin-binding small molecules |
| DK2019104T3 (da) * | 2007-07-19 | 2013-12-16 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf |
| CN102365021B (zh) * | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| KR101947176B1 (ko) * | 2009-06-03 | 2019-02-12 | 이뮤노젠 아이엔씨 | 접합 방법 |
-
2012
- 2012-12-13 KR KR20147019143A patent/KR20140107418A/ko not_active Withdrawn
- 2012-12-13 EA EA201491173A patent/EA201491173A1/ru unknown
- 2012-12-13 HK HK15103864.0A patent/HK1203364A1/xx unknown
- 2012-12-13 EP EP12856692.4A patent/EP2790724A4/en not_active Withdrawn
- 2012-12-13 MX MX2014007125A patent/MX2014007125A/es unknown
- 2012-12-13 BR BR112014014464A patent/BR112014014464A2/pt not_active IP Right Cessation
- 2012-12-13 CA CA 2859444 patent/CA2859444A1/en not_active Abandoned
- 2012-12-13 CN CN201280068773.2A patent/CN104093425A/zh active Pending
- 2012-12-13 SG SG10201604747WA patent/SG10201604747WA/en unknown
- 2012-12-13 AU AU2012352210A patent/AU2012352210A1/en not_active Abandoned
- 2012-12-13 JP JP2014547433A patent/JP2015504869A/ja active Pending
- 2012-12-13 US US14/365,305 patent/US20140350228A1/en not_active Abandoned
- 2012-12-13 SG SG11201403179QA patent/SG11201403179QA/en unknown
- 2012-12-13 WO PCT/US2012/069527 patent/WO2013090590A1/en not_active Ceased
-
2014
- 2014-06-12 IL IL233086A patent/IL233086A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140350228A1 (en) | 2014-11-27 |
| BR112014014464A8 (pt) | 2017-06-13 |
| SG11201403179QA (en) | 2014-07-30 |
| HK1203364A1 (en) | 2015-10-30 |
| WO2013090590A1 (en) | 2013-06-20 |
| SG10201604747WA (en) | 2016-08-30 |
| CN104093425A (zh) | 2014-10-08 |
| IL233086A0 (en) | 2014-07-31 |
| CA2859444A1 (en) | 2013-06-20 |
| MX2014007125A (es) | 2015-04-16 |
| KR20140107418A (ko) | 2014-09-04 |
| EP2790724A4 (en) | 2015-08-05 |
| EP2790724A1 (en) | 2014-10-22 |
| AU2012352210A1 (en) | 2014-07-24 |
| JP2015504869A (ja) | 2015-02-16 |
| EA201491173A1 (ru) | 2014-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014464A2 (pt) | uso de n-hidroxisuccinimida para melhorar a estabilidade do conjugado | |
| UA111341C2 (uk) | Аматоксиновий кон'югат з покращеними лінкерами | |
| CY1121321T1 (el) | Παρασκευη συζευγματων αντισωματoς-μεϋτανσινoεiδoυς δια μιας μεθοδου μιας βαθμιδας | |
| CL2019002858A1 (es) | Conjugación de un fármaco citotóxico con enlace bis. | |
| MX2024002632A (es) | Enlazadores que contienen peptido para conjugados anticuerpo-farmaco. | |
| DOP2012000038A (es) | Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos | |
| EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
| EA201792652A3 (ru) | Новые производные майтанзиноида с пептидным линкером и их конъюгаты | |
| MY171008A (en) | Preparation of maytansinoid antibody conjugates by a one-step process | |
| MX2013011201A (es) | Proceso para la elaboracion de conjugados de mejor homogeneidad. | |
| EA201590171A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
| IN2015DN00694A (enExample) | ||
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| EA201590705A1 (ru) | ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ | |
| NZ588884A (en) | Cross-linkers and their uses | |
| MX344009B (es) | Conjugados de amatoxinas con enlaces mejorados. | |
| MX2012000575A (es) | Conjugados de epsilon-polilisina y uso de los mismos. | |
| BR112014006822A2 (pt) | proteínas de ligação ao antígeno cd27l | |
| CY1116835T1 (el) | Νεο ευρωπαϊκο στελεχος toy prrsv | |
| EA201401254A1 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
| PH12014501229A1 (en) | Antibody-drug conjugates and related compounds, compositions, and methods | |
| EA201590172A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
| MX379386B (es) | Proceso de glicoconjugación. | |
| MX375715B (es) | Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos. | |
| MX2015002482A (es) | Composicion inmunogenica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |